Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.12 +0.00%

+$0.00 today

Market cap
$605.45M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 0.84M

Average 0.54M

Returns on capital

Bicara Therapeutics Inc. Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-34.4%

avg 36.8%

ROIC

-38.6%

avg 36.8%

ROA

-32.0%

avg -157.7%

Analysis

ROA is currently the strongest return metric at -32.0% versus its period average of -157.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Claire Mazumdar Clemon

Chief Executive Officer & DirectorUSD 927.69K37——

Ryan Cohlhepp

President, Chief Operating Officer & DirectorUSD 858.4K4934.25K0.06%

Angela Windt

Vice President & Head of Regulatory Affairs————

Jennifer Larson

CFO, Treasurer & Principal Accounting Officer—510<0.01%

Lara S. Meisner

Chief Legal Officer, Compliance Officer & Corporate Secretary—54——

Pauline Dufresne

Chief People Officer————

Rachel Frank

Vice President of Investor Relations and Corporate Communications————

Rachel Salazar

SVP of R&D Strategy and Operations————

Sathish Hasige

Senior Vice President and Head of Technical Operations & Supply Chain————

Jeltje Schulten

Senior Vice President of Clinical & Medical Affairs————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 8, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$4.80M

Sells

55

$9.12M

Net Transaction Value

−$4.32M

Net selling

Most Active

Cohlhepp Ryan

23 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 8, 26

Cohlhepp Ryan

Direct

Sell$80.7K
Sep 8, 26

Cohlhepp Ryan

Direct

Sell$320.1K
Aug 10, 26

Hyep Ivan

Direct

Sell$349.6K
Aug 10, 26

Mazumdar Claire

Direct

Sell$279.8K
Aug 10, 26

Cohlhepp Ryan

Direct

Sell$524.5K
Jul 10, 26

Mazumdar Claire

Direct

Sell$831
Jul 10, 26

Mazumdar Claire

Direct

Sell$283.4K
Jul 9, 26

Cohlhepp Ryan

Direct

Sell$15.5K
Jul 8, 26

Cohlhepp Ryan

Direct

Sell$656.7K
Jul 8, 26

Cohlhepp Ryan

Direct

Sell$128.3K

1–10 of 57

Summary

Insiders reported 2 buys worth $4.80M and 55 sells worth $9.12M over the last 12 months. That adds up to net selling of $4.32M. Cohlhepp Ryan was the most active insider with 23 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Bicara Therapeutics Inc. Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about BCAX's management, answered from reported figures.

Who manages BCAX?

Bicara Therapeutics Inc. Common Stock (BCAX) lists 10 active executives. The top listed executive is Angela Windt, Vice President & Head of Regulatory Affairs.

Are BCAX insiders buying or selling?

Recent insider activity shows net buying of $24.72M.